Novel TGF-β inhibitors ready for prime time in onco-immunology.
Novel TGF-β inhibitors ready for prime time in onco-immunology.
复制标题
DOI：
10.1080/2162402x.2016.1257453
复制
发表时间：
2017
期刊：
影响因子：
7.2
通讯作者：
Raymond E
中科院分区：
文献类型：
--
作者：
de Gramont A;Faivre S;Raymond E
转化生长因子(TGF)-β抑制剂已经被开发了几十年，最明显的结果是有希望的候选者。从2016年ASCO会议上的最新临床结果来看，越来越多的证据表明，我们已经从有希望的药物提名转向了有效的药物提名。
Transforming Growth Factor (TGF)-β inhibitors have been in development for decades with the outmost results of being promising candidates. From the latest clinical results at the 2016 ASCO meeting converging evidences suggest that we have moved from promising to effective drug nominees.